ダウンロード数: 269
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
31_2215.pdf | 264.69 kB | Adobe PDF | 見る/開く |
タイトル: | 表在性膀胱腫瘍に対する4'-epi-Adriamycin膀胱腔内注入療法(Randomized Study) |
その他のタイトル: | Intravesical chemotherapy with 4'-EPI-adriamycin in patients with superficial bladder tumors (randomized study) |
著者: | 津島, 知靖 松村, 陽右 尾崎, 雄治郎 赤木, 隆文 小浜, 常昭 那須, 保友 大森, 弘之 |
著者名の別形: | Tsushima, Tomoyasu Matsumura, Yosuke Ozaki, Yujiro Akagi, Takafumi Obama, Tsuneaki Nasu, Yasutomo Ohmori, Hiroyuki |
キーワード: | Adult Aged Doxorubicin/administration & dosage/adverse effects/therapeutic use Drug Administration Schedule Epirubicin Female Humans Male Middle Aged Random Allocation Urinary Bladder Urinary Bladder Neoplasms/drug therapy/pathology |
発行日: | Dec-1985 |
出版者: | 泌尿器科紀要刊行会 |
誌名: | 泌尿器科紀要 |
巻: | 31 |
号: | 12 |
開始ページ: | 2215 |
終了ページ: | 2218 |
抄録: | randomized studyにて検討したところ, EPIは60 mgを生塩水30 mlに溶解して, 1日1回, 3日間連続で4日間休止, これを2週連続で施行し計時的6回注入するのが, 効果及び副作用の両面から優れた方法であるとの結果が得られた Thirty-seven cases of superficial bladder cancer were treated with 4'-epi-adriamycin (EPI) by intravesical instillation to investigate the optimal dosage and treatment schedule. Patients were randomized into either group A: 50 mg/day for 6 days (regimen A) or group B: 60 mg/day for 3 days X 2 courses with 4 days interval (regimen B). Seventeen cases were evaluated in both groups, three cases were ineligible in group B. Patient characteristics such as age, sex, size of tumor, stage and grade were not significantly different between the two groups. Response rates were 41.2% (group A) and 70.6% (group B), while incidence of toxicity was 47.1% and 50.0% respectively. There is a trend in favor of regimen B which deserves to be more extensively verified. |
URI: | http://hdl.handle.net/2433/118689 |
PubMed ID: | 3868934 |
出現コレクション: | Vol.31 No.12 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。